DOCSLIB.ORG

A 45-Year-Old Man with Weakness and Myalgia After Orthopedic Surgery Rocio Vazquez Do Campo, Jason Siegel, Eric Goldstein, Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A 45-Year-Old Man with Weakness and Myalgia After Orthopedic Surgery Rocio Vazquez Do Campo, Jason Siegel, Eric Goldstein, Et Al RESIDENT & FELLOW SECTION Clinical Reasoning: Section Editor A 45-year-old man with weakness and John J. Millichap, MD myalgia after orthopedic surgery Rocio Vazquez do SECTION 1 On examination, the patient had tenderness in Campo, MD A 45-year-old man underwent rotator cuff surgery and both thighs. There were no skin changes, swelling, Jason Siegel, MD developed fatigue and generalized myalgia postopera- or erythema. He had multiple surgical scars in the Eric Goldstein, MD tively. After 4 weeks of mild symptoms, he experienced right shoulder and mild weakness in proximal limb Elliot Dimberg, MD severe muscle aches and bilateral leg weakness after walk- and cervical muscles. Biceps and patellar reflexes were ing 1.5 miles, prompting him to seek medical attention. diminished bilaterally. He was able to rise from a chair The patient had a history of chronic pain syn- using his arms, but had difficulty ambulating due to Correspondence to drome and multiple orthopedic surgeries. He had leg pain. The remainder of the examination was Dr. Vazquez do Campo: no pertinent family history. He denied foreign travel, vazquezdocampo.rocio@mayo. unremarkable. edu consumption of alcohol, tobacco, illicit drugs, nutri- Questions for consideration: tional supplements, or herbal remedies. He denied risky sexual behaviors. He was taking trazodone, oxy- 1. What is the differential diagnosis? codone, and omeprazole. 2. What studies should be obtained next? GO TO SECTION 2 From the Department of Neurology, Mayo Clinic Jacksonville, FL. Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. © 2017 American Academy of Neurology e185 ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited. SECTION 2 given the diffuse nature of the symptoms. Due to the This patient presents with diffuse myalgia after patient’s history of chronic pain, fibromyalgia and a minimally invasive surgical procedure and is found polymyalgia rheumatica are possible, but objective to have mild proximal weakness on examination. Myal- weakness would not be expected. Finally, acute pain gia, or muscle pain, is encountered in a variety of condi- exacerbation and deconditioning after surgery are tions, ranging from benign causes, such as strenuous diagnoses of exclusion. physical activity, to life-threatening conditions. The first Initial laboratory evaluation in patients with myal- step in the evaluation of patients with myalgia is to estab- gia should include complete blood count, serum cal- lish a timeframe from symptom onset and precipitating cium and other electrolytes, urinalysis, renal and liver factors. Acute onset is observed after trauma, surgery, or function tests, thyroid-stimulating hormone (TSH), strenuous exercise. If symptoms develop insidiously, and creatinine kinase (CK) levels. Depending on medications (statins, fibrates), rheumatologic conditions other symptoms, risk factors, and examination find- (polymyalgia rheumatica), chronic infections, or meta- ings, blood cultures, erythrocyte sedimentation rate bolic disorders (hypercalcemia, hypothyroidism, or hy- (ESR), C-reactive protein (CRP), or rheumatologic percortisolism) should be considered. studies may be helpful. The distribution of myalgia helps narrow the differ- In this patient, blood count and chemistries were ential diagnosis. Myalgia involving proximal appendic- normal. CK levels were elevated at 86,300 U/L ular muscles points towards a primary muscle disease (normal ,330 U/L). Transaminases were also elevated: or rheumatologic or orthopedic disorders. When dif- alanine aminotransferase (ALT) was 1,260 U/L (normal fuse, an infectious process, especially viral and parasitic, ,55 U/L) and aspartate aminotransferase (AST) was deserves consideration. Rhabdomyolysis from varied 3,270 U/L (normal ,48 U/L). Lactate dehydrogenase etiologies can also present with diffuse myalgia.1,2 (LDH) was 1,360 U/L (normal ,220 U/L). Alkaline Detection of objective weakness is important, but phosphatase and g-glutamine transpeptidase (GGT) frequently confounded by pain limiting maximal levels were normal. Urine dipstick revealed proteinuria effort on examination. Assessment of neck flexors and was positive for blood (1–3 erythrocytes per high- and extensors may be helpful. Both myopathies and powered field on microscopy). ESR and CRP were polyradiculopathies can present with weakness and moderately elevated. TSH was normal. Hepatitis serol- pain in proximal limbs. In this patient, sensation ogies, HIV, procalcitonin, blood cultures, and urine was preserved and reflexes mildly diminished, more drug screen were negative. suggestive of a myopathy. The temporal relationship Questions for consideration: with a surgical procedure requires exclusion of an in- traoperative or postoperative infection or an underly- 1. How do you interpret these results? ing metabolic or endocrine disorder exacerbated by 2. What information would help narrow the differ- surgical stress. Direct trauma from surgery is unlikely ential diagnosis? GO TO SECTION 3 e186 Neurology 88 May 9, 2017 ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited. SECTION 3 muscle enzymes, myoglobinuria, and generalized The patient had markedly elevated CK, AST, ALT, myalgia. The elevated ESR and CRP likely resulted and LDH levels. These enzymes are present in skele- from an inflammatory response to muscle injury. tal muscle cells and are released into the circulation as The most important next step was to provide IV the result of muscle damage and membrane disrup- hydration to preserve renal function and to exclude tion as seen in rhabdomyolysis. Transaminases and life-threatening complications (cardiac arrhythmias LDH are also found in liver tissue, but in the presence from electrolyte disturbances, severe metabolic acido- of hyperCKemia, these enzyme elevations are more sis, and organ failure). likely due to muscle breakdown than liver injury. In Once stabilized, the patient reported recurrent ep- addition, GGT and alkaline phosphatase, more spe- isodes of diffuse muscle aches and occasional dark cific markers of liver damage, were normal in this urine, which would subside within hours to days, patient. Other muscle components, including myo- after exercise dating back to his teenage years. He globin and other small proteins, are also released in experienced similar symptoms episodically in the con- the setting of muscle breakdown and excreted in text of surgical procedures and illnesses. Over the past urine resulting in proteinuria. Myoglobin has molec- year, he had developed exercise intolerance and could ular similarities with hemoglobin and also turns urine not walk more than 150 yards without experiencing dark; therefore the presence of myoglobin in urine severe leg pain. may be falsely labeled as hematuria. A few erythro- Questions for consideration: cytes under direct urine visualization, like in this patient, suggests myoglobinuria. 1. What are common causes of rhabdomyolysis? We concluded that our patient had rhabdomyoly- 2. What is the most likely cause of rhabdomyolysis in sis causing increased serum levels of CK and other this patient? GO TO SECTION 4 Neurology 88 May 9, 2017 e187 ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited. SECTION 4 metabolism. While in glycolytic metabolic defects, The causes of rhabdomyolysis can be divided into 3 patients usually have cramps induced by light exer- categories: traumatic, exertional, and nontraumatic cise or brief isometric contractions, symptoms in nonexertional. Trauma includes direct muscle dam- disorders of lipid metabolism are dominated by age or compression from prolonged immobilization myalgia triggered by prolonged or intense exercise against a hard surface. The second category includes and other situations that increase energy demand conditions in which energy production or utilization from fat (fasting, fever, trauma, surgery).4,5 Symp- by myocytes is insufficient to meet metabolic de- toms in our patient were precipitated by the stress of mands, such as hyperthermia, convulsive seizure, vig- surgery and possibly intraoperative anesthetics, and orous exercise, and metabolic myopathies. The third further worsened by prolonged exertion (walking group includes miscellaneous conditions (infections, a long distance), therefore a metabolic myopathy electrolyte imbalances, drug or toxin-related, muscle due to a lipid metabolism defect was suspected. ischemia, or inflammatory myopathies).3 We ordered serum levels of free and total carnitine, The cause of rhabdomyolysis in this patient falls acylcarnitines, and urine organic acids. Concentra- into the second category. He had a longstanding his- tions of long-chain acylcarnitines, particularly C16 tory of exercise intolerance beginning in childhood and C18:1 species, were elevated with an otherwise with recurrent myalgia and pigmenturia triggered normal carnitine profile (total plasma 76 nmol/mL by exercise and stress, suggesting a disorder of [normal 34–78 nmol/mL]). Further serologic meta- energy metabolism. In addition, after the attack bolic screening was unremarkable. Electrodiagnostic his strength improved and muscle enzymes normal- studies and muscle biopsy were deferred as both ized, indicating cessation of damage after resolution provide limited information in the setting of rhab- of the situation of metabolic stress. These features
Load more

Recommended publications
  • Opioid-Induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations
    SPECIAL TOPIC SERIES Opioid-induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations Larry F. Chu, MD, MS (BCHM), MS (Epidemiology),* Martin S. Angst, MD,* and David Clark, MD, PhD*w treatment of acute and cancer-related pain. However, Abstract: Opioid-induced hyperalgesia (OIH) is most broadly recent evidence suggests that opioid medications may also defined as a state of nociceptive sensitization caused by exposure be useful for the treatment of chronic noncancer pain, at to opioids. The state is characterized by a paradoxical response least in the short term.3–14 whereby a patient receiving opioids for the treatment of pain Perhaps because of this new evidence, opioid may actually become more sensitive to certain painful stimuli. medications have been increasingly prescribed by primary The type of pain experienced may or may not be different from care physicians and other patient care providers for the original underlying painful condition. Although the precise chronic painful conditions.15,16 Indeed, opioids are molecular mechanism is not yet understood, it is generally among the most common medications prescribed by thought to result from neuroplastic changes in the peripheral physicians in the United States17 and accounted for 235 and central nervous systems that lead to sensitization of million prescriptions in the year 2004.18 pronociceptive pathways. OIH seems to be a distinct, definable, One of the principal factors that differentiate the use and characteristic phenomenon that may explain loss of opioid of opioids for the treatment of pain concerns the duration efficacy in some cases. Clinicians should suspect expression of of intended use.
    [Show full text]
  • Aetiology of Fibrositis
    Ann Rheum Dis: first published as 10.1136/ard.6.4.241 on 1 January 1947. Downloaded from AETIOLOGY OF FIBROSITIS: A REVIEW BY MAX VALENTINE From a review of systems of classification of fibrositis (National Mineral Water Hospital, Bath, 1940; Devonshire Royal Hospital, Buxton, 1940; Ministry of Health Report, 1924; Harrogate Royal Bath Hospital Report, 1940; Ray, 1934; Comroe, 1941 ; Patterson, 1938) the one in use at the National Mineral Water Hospital, Bath, is considered most valuable. There are five divisions of fibrositis as follows: (a) intramuscular, (b) periarticular, (c) bursal and tenosynovial, (d) subcutaneous, (e) perineuritic, the latter being divided into (i) brachial (ii) sciatic, etc. Laboratory Tests No biochemical abnormalities have been demonstrated in fibrositis. Mester (1941) claimed a specific test for " rheumatism ", but Copeman and Stewart (1942) did not find it of value and question its rationale. The sedimentation rate is usually normal or may be slightly increased; this is confirmed by Kahlmeter (1928), Sha;ckle (1938), and Dawson and others (1930). Miller copyright. and Gibson (1941) found a slightly increased rate in 52-3% of patients, and Collins and others (1939) found a (usually) moderately increased rate in 35% of cases tested. Case Analyses In an investigation Valentine (1943) found an incidence of fibrositis of 31-4% (60% male) at a Spa hospital. (Cf. Ministry of Health Report, 1922, 30-8%; Buxton Spa Hospital, 1940, 49 5%; Bath Spa Hospital, 1940, 22-3%; Savage, 1941, 52% in the Forces.) Fibrositis was commonest http://ard.bmj.com/ between the ages of40 and 60; this is supported by the SpaHospital Report, Buxton, 1940.
    [Show full text]
  • Guidline for the Evidence-Informed Primary Care Management of Low Back Pain
    Guideline for the Evidence-Informed Primary Care Management of Low Back Pain 2nd Edition These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. Guideline Disease/Condition(s) Targeted Specifications Acute and sub-acute low back pain Chronic low back pain Acute and sub-acute sciatica/radiculopathy Chronic sciatica/radiculopathy Category Prevention Diagnosis Evaluation Management Treatment Intended Users Primary health care providers, for example: family physicians, osteopathic physicians, chiro- practors, physical therapists, occupational therapists, nurses, pharmacists, psychologists. Purpose To help Alberta clinicians make evidence-informed decisions about care of patients with non- specific low back pain. Objectives • To increase the use of evidence-informed conservative approaches to the prevention, assessment, diagnosis, and treatment in primary care patients with low back pain • To promote appropriate specialist referrals and use of diagnostic tests in patients with low back pain • To encourage patients to engage in appropriate self-care activities Target Population Adult patients 18 years or older in primary care settings. Exclusions: pregnant women; patients under the age of 18 years; diagnosis or treatment of specific causes of low back pain such as: inpatient treatments (surgical treatments); referred pain (from abdomen, kidney, ovary, pelvis,
    [Show full text]
  • Headache and Chronic Pain in Primary Care
    FAMILY PRACTICE GRAND ROUNDS Headache and Chronic Pain in Primary Care Thomas Greer, MD, MPH, Wayne Katon, MD, Noel Chrisman, PhD, Stephen Butler, MD, Dee Caplan-Tuke, MSW Seattle, W a s h in g t o n R. THOMAS GREER (Assistant Professor, Depart­ automobile accident while vacationing in another state Dment of Family Medicine): The management of pa­ and suffered multiple contusions and rib fractures. Oral tients with chronic headaches is difficult and often a source methadone had been prescribed at her second clinic visit of discord between the patient and his or her physician. when other oral narcotics failed to control her pain. She The patient with chronic headaches presented in this con­ also had a long history of visits for headaches, treated with ference illustrates most of the common problems encoun­ injections of a narcotic, usually meperidine, and oral co­ tered in the diagnosis, treatment, and management of pa­ deine. tients with other kinds of chronic pain as well. As her acute injuries healed and she was tapered off the methadone, her chronic headaches emerged as a signifi­ cant problem. Within a few months the patient was reg­ EPIDEMIOLOGY ularly requesting oral codeine for the management of her severe, intractable headaches. More than 40 million Americans consult physicians each In early September she was brought to our emergency year for complaints of headache.1 The National Ambu­ department by ambulance following an apparent seizure. latory Medical Care Survey, which gathered information Witnesses reported that the patient had “jerking move­ on approximately 90,000 patient visits to a nationally ments.” There was no incontinence; and the ambulance representative sample of physicians, determined that personnel found the patient to be irritable and disoriented headache was the second most common chronic pain but with stable vital signs.
    [Show full text]
  • Anaphylaxis and Rhabdomyolysis. Any Early Relationship?
    Review Article Crit Care & Shock (2012) 15:88-94 Anaphylaxis and rhabdomyolysis. Any early relationship? Amr S. Omar Abstract Introduction: Rhabdomyolysis (RML) had been identified Results: Both patients survived, both developed RML in different traumatic and non-traumatic conditions; shortly after admission, evidenced by 5-fold or greater few reports described its association with anaphylaxis. increase in serum CPK. They had transient hypotension We report two cases of anaphylaxis both complicated through the presentation, but none of them had persistent with RML. shock requiring vasopressors or complicated with acute renal failure. Aim of the work: To discus the possible casual relation between anaphylaxis and RML and so the value of early Conclusion: We observed rapid increase in serum CPK screening of creatine phosphokinase (CPK) in patients in our two cases suggesting the potential benefits of early with anaphylaxis. assessment of CPK in such patients which may amplify early goal guided management and avoiding logistic Setting: Two patients were enrolled in a multidisciplinary organ dysfunction. intensive care unit. Key words: Rhabdomyolysis, anaphylaxis. Introduction Background Pathophysiology Anaphylaxis is an acute, potentially lethal, multisystem Organ system involvement in anaphylaxis varies from syndrome resulting from the sudden release of mast cell species to species and determines the clinical manifestations and basophile-derived mediators into the circulation. (1) observed. Factors that determine a specific “shock organ” Rhabdomyolysis was first described in the victims of crush include variations in the immune response, the location of injury during the 1940-1941 London, England blitzkrieg smooth muscle, and the distribution, rate of degradation, bombing raids of World War II.
    [Show full text]
  • Clinical Data Mining Reveals Analgesic Effects of Lapatinib in Cancer Patients
    www.nature.com/scientificreports OPEN Clinical data mining reveals analgesic efects of lapatinib in cancer patients Shuo Zhou1,2, Fang Zheng1,2* & Chang‑Guo Zhan1,2* Microsomal prostaglandin E2 synthase 1 (mPGES‑1) is recognized as a promising target for a next generation of anti‑infammatory drugs that are not expected to have the side efects of currently available anti‑infammatory drugs. Lapatinib, an FDA‑approved drug for cancer treatment, has recently been identifed as an mPGES‑1 inhibitor. But the efcacy of lapatinib as an analgesic remains to be evaluated. In the present clinical data mining (CDM) study, we have collected and analyzed all lapatinib‑related clinical data retrieved from clinicaltrials.gov. Our CDM utilized a meta‑analysis protocol, but the clinical data analyzed were not limited to the primary and secondary outcomes of clinical trials, unlike conventional meta‑analyses. All the pain‑related data were used to determine the numbers and odd ratios (ORs) of various forms of pain in cancer patients with lapatinib treatment. The ORs, 95% confdence intervals, and P values for the diferences in pain were calculated and the heterogeneous data across the trials were evaluated. For all forms of pain analyzed, the patients received lapatinib treatment have a reduced occurrence (OR 0.79; CI 0.70–0.89; P = 0.0002 for the overall efect). According to our CDM results, available clinical data for 12,765 patients enrolled in 20 randomized clinical trials indicate that lapatinib therapy is associated with a signifcant reduction in various forms of pain, including musculoskeletal pain, bone pain, headache, arthralgia, and pain in extremity, in cancer patients.
    [Show full text]
  • AAFP Chronic Pain Toolkit
    AAFP Chronic Pain Toolkit PAIN ASSESSMENT | Section 1 OVERVIEW Assessment of chronic pain should be multidimensional. Consideration should be given to several domains, including the physiological features of pain and its contributing factors, with physicians and other clinicians assessing patients for function, quality of life, mental health, and emotional health. In addition to a complete medical and medication history typically obtained at an office visit, documentation should be obtained about pain intensity, location, duration, and factors that aggravate or alleviate pain. A physical exam should include musculoskeletal and neurological components, as appropriate. Diagnostic testing and imaging may also be considered for some types of chronic pain. Many organizations, including the AAFP, recommend against imaging for low back pain within the first six weeks of treatment unless there are reasons for the imaging. These reasons may include concerns of underlying conditions, such as severe or progressive neurological deficits, or if osteomyelitis is suspected.1 Periodic reassessments of chronic pain and treatment should focus on evaluating improvements in physical health; mental and emotional health; progress towards functional treatment goals; and effectiveness and tolerability of medications for chronic pain treatment. Currently, there are no universally adopted guidelines or recommendations for assessment of chronic pain. The use of appropriate assessment tools can assist in diagnostic assessment, management, reassessment, and monitoring of treatment effects. Multiple tools are available, with many embedded in electronic health record (EHR) systems. Pain Assessment Tools The table on the next page includes selected tools for pain assessment included in this toolkit, along with links and reference to additional tools. Assessments about other relevant domains are covered in Functional and Other Assessments (Section 2).
    [Show full text]
  • (RSV) Infection? an Analysis Using the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) RSV Database
    Does Ribavirin Impact on the Hospital Course of Children With Respiratory Syncytial Virus (RSV) Infection? An Analysis Using the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) RSV Database Barbara J. Law, MD*; Elaine E. L. Wang, MDCM‡; Noni MacDonald, MD§; Jane McDonald, MDi; Simon Dobson, MD¶; Francois Boucher, MD#; Joanne Langley, MD**; Joan Robinson, MD‡‡; Ian Mitchell, MD§§; and Derek Stephens MSc‡ ABSTRACT. Objectives. To determine the relation- 20.6%, 20.9%, 15.5%, 15.2%, and 13.3%, respectively. ship between receipt of aerosolized ribavirin and the Across the subsets ribavirin use ranged from 36% to 57% hospital course of high-risk infants and children with of ventilated patients and 6% to 39% of nonventilated respiratory syncytial virus (RSV) lower respiratory infec- patients. For nonventilated patients in each subset the tion (LRI). median RSV-attributable hospital length of stay (RSV- Methods. The 1993–1994 Pediatric Investigators Col- LOS) was 2 to 3 days longer for ribavirin recipients and laborative Network on Infections in Canada (PICNIC) the duration of hypoxia was significantly increased. Du- RSV database consists of prospectively enrolled children ration of intensive care unit (ICU) stay was also increased with acute RSV LRI, admitted to nine Canadian pediatric for all ribavirin-treated subgroups except those with tertiary care centers. After excluding cases with compro- CHD. In contrast, for ventilated patients, ribavirin ther- mised immunity and/or nosocomial infection, subsets apy was
    [Show full text]
  • Anorexia/Cachexia Heart Failure Symptom Management Guideline for Adults, Age 19 and Older in British Columbia
    Anorexia/Cachexia Heart Failure Symptom Management Guideline For adults, age 19 and older in British Columbia What is anorexia? Anorexia is a syndrome characterized by some or all of the following symptoms: loss of appetite, nausea, early satiety, weakness, fatigue, food aversion, and significant physical and/or psychological symptoms. Causes of anorexia are multifactorial and include fatigue, dyspnea, medication side-effects, nausea, depression, anxiety and sodium restricted diets, which may all be found in patients with heart failure. What is cachexia? Cachexia is a syndrome characterized by severe body weight, fat and muscle loss and increased protein catabolism due to underlying disease. The prevalence of cachexia is 16–42% in the heart failure population and is associated with a 50%, 18 month mortality risk independent of variables such as ejection fraction, age and functional ability. How is cachexia diagnosed? Chronic condition with >5% weight loss in <12 months; or body mass index (BMI) <20kg/m2; and 3 out of 5 additional criteria: 1) Fatigue, 2) Decreased muscle strength, 3) Anorexia, 4) Low muscle mass, 5) Abnormal biochemistry *Blood testing to diagnose cachexia in advanced stages of disease is not advocated. Reminder: Malnutrition also affects prognosis in patients with heart failure and is often found in early transitions of the disease. However this symptom management guideline will focus on the assessment and treatment of anorexia and cachexia. Approach to Managing Anorexia/Cachexia Assessment History: When did weight loss begin? How much weight was lost? Obtain baseline (dry) weight. How is [the patients] appetite? What do they eat or drink on a typical day? How has weight loss affected mood? Ask about: nausea, early satiety, dyspnea, poor oral hygiene, dysphagia, malabsorption, bowel habits.
    [Show full text]
  • Pain Management in People Who Have OUD; Acute Vs. Chronic Pain
    Pain Management in People Who Have OUD; Acute vs. Chronic Pain Developer: Stephen A. Wyatt, DO Medical Director, Addiction Medicine Carolinas HealthCare System Reviewer/Editor: Miriam Komaromy, MD, The ECHO Institute™ This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under contract number HHSH250201600015C. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government. Disclosures Stephen Wyatt has nothing to disclose Objectives • Understand the complexities of treating acute and chronic pain in patients with opioid use disorder (OUD). • Understand the various approaches to treating the OUD patient on an agonist medication for acute or chronic pain. • Understand how acute and chronic pain can be treated when the OUD patient is on an antagonist medication. Speaker Notes: The general Outline of the module is to first address the difficulties surrounding treating pain in the opioid dependent patient. Then to address the ways that patients with pain can be approached on either an agonist of antagonist opioid use disorder treatment. Pain and Substance Use Disorder • Potential for mutual mistrust: – Provider • drug seeking • dependency/intolerance • fear – Patient • lack of empathy • avoidance • fear Speaker Notes: It is the provider that needs to be well educated and skillful in working with this population. Through a better understanding of opioid use disorders as a disease, the prejudice surrounding the encounter with the patient may be reduced.
    [Show full text]
  • Employees Calling About RTW Clearance
    1. Employee should do home quarantine for 7 days Employees calling and consult their physician about RTW clearance 2. Employee must call their own manager to call in Community/General Exposure OR sick as per their usual policy IP&C or Supervisor Confirmed Exposure 3. To return to work, employee must be fever-free without antipyretic for 3 days (72 hours) AND 1. Confirm that employee symptoms improveD AND finisheD 7-day home has finished 7-day home quarantine Community/General/ Travel/ quarantine AND fever-free Day Zero= First Day of Symptoms without antipyretics for 3 CDC Level 2/3 Country* COVID Permitted work on the 8th day days (72 hours) AND Exposure Employee must call the WHS hotline back symptoms have improved then for RTW clearance Employees who call-in 2. Employee should wear Community/General/ 4.Fill out RTW form to place employee off-duty with non-CLI surgical face mask during Unknown COVID Symptoms, but still entire shift while at work exposure (any not feeling well: going forward 3. If employee has been off- exposure that is NOT Please remember to stay duty for 8 or more calendar “Infection Prevention home if you don’t feel days, then email and Control (IP&C) well. Healthcare team confirmed) [email protected] Personnel must not work with doctor’s note simply sick. Follow usual steps stating that they sought for take sick day and care/treatment for COVID- contact their manager. Note: loss of smell/taste alone does If there are NO like symptoms ANY 4.Employee should update NOT constitute CLI per WHS No RTW form needed for symptoms following their manager COVID-19 Symptoms: guidelines Employees with NO non-CLI exposure or travel, 5.
    [Show full text]
  • Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes
    Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes Type 2 Diabetes ranges from predominantly insulin resistant with relative insulin deficiency to predominantly an insulin secretory defect with insulin resistance, American Diabetes Association, 2010. (ICD 9 code 250.0) Prevalence • 23.6 million Americans have diabetes – 7.8% of U.S. population. Of these, 5.7 million do not know they have the disease. • 1.6 million people ≥20 years of age are diagnosed with diabetes annually. • 90–95% of diabetic patients have Type 2 Diabetes. Manifestations Clinical of untreated diabetes • High blood glucose level • Excessive thirst • Frequent urination • Weight loss • Fatigue Oral • Increased risk of dental caries due to salivary hypofunction • Accelerated tooth eruption with increasing age • Gingivitis with high risk of periodontal disease (poor control increases risk) • Salivary gland dysfunction leading to xerostomia • Impaired or delayed wound healing • Taste dysfunction • Oral candidiasis • Higher incidence of lichen planus Other Potential Disorders/Concerns • Ketoacidosis, kidney failure, gastroparesis, diabetic neuropathy and retinopathy • Poor circulation, increased occurrence of infections, and coronary heart disease Management Medication The list of medications below are intended to serve only as a guide to facilitate the dental professional’s understanding of medications that can be used for Type 2 Diabetes. Medical protocols can vary for individuals with Type 2 Diabetes from few to multiple medications. ACTION TYPE BRAND NAME/GENERIC SIDE EFFECTS Enhance insulin Sulfonylureas Glipizide (Glucotrol) Angioedema secretion Glyburide (DiaBeta, Fluconazoles may increase the Glynase, Micronase) hypoglycemic effect of glipizide Glimepiride (Amaryl) and glyburide. Tolazamide (Tolinase, Corticosteroids may produce Diabinese, Orinase) hyperglycemia. Floxin and other fluoroquinolones may increase the hypoglycemic effect of sulfonylureas.
    [Show full text]